Clinical trials: Glioblastoma, WHO Grade IV
Glioblastom WHO Grade 4
FCI-Glioblastoma Study
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can tell the difference between tumour growth (progression) and 'pseudo-progression' (which looks like tumour but is not…
- Trial name
- NCT07443176
- Testing
- Baseline Field-Cycling Imaging research scan, Baseline 3T MRI research scan, Second Field-Cycling Imaging research scan
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- University of Aberdeen
Brain Injuries, Acute, Brain Tumor Adult
PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors
Serious brain diseases and injuries affect not only the person who becomes ill or injured, but also their family. Relatives of people with acquired brain injury (ABI) or malignant brain tumor (MBT) often take on a major role in…
- Conditions
- Brain Injuries, Acute, Brain Tumor Adult, Brain (Nervous System) Cancers, Traumatic Brain Injuries
- Trial name
- PIRe (NCT07590726)
- Testing
- Supportive Care
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals
Glioma, Glioma (Diagnosis)
GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-GBM can help detect a specific molecular type of brain tumour called IDH wildtype glioblastoma using routine MRI scans.
- Conditions
- Glioma, Glioma (Diagnosis), Glioblastom WHO Grade 4, IDH Wildtype Glioblastoma
- Trial name
- GliomaAI-GBM (NCT07673692)
- Testing
- GliomaAI-GBM
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Glioblastoma Multiforme
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis.
- Trial name
- NCT05423210
- Testing
- Atezolizumab + FSRT radiation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stony Brook University
Glioblastoma, Gliosarcoma
EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
Please note that enrollment on this study terminated early due to the end of grant funding. Newly diagnosed WHO grade IV malignant glioma subjects who are eligible were enrolled following surgery to remove their brain tumor.
- Trial name
- ExCeL (NCT02664363)
- Testing
- EGFRvIII CAR T cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Daniel Landi
Glioblastoma, Astrocytoma, Grade III
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
Several investigations suggest neural stem cells located in the subventricular region play an active role in promoting or even initiating cortical malignant glioma growth.
- Conditions
- Glioblastoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Malignant Glioma
- Trial name
- NCT03956706
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Sponsor
- Northwell Health
Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV)
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
This is an open label, single arm, prospective, and pilot study. Eligible patients will be enrolled after acquiring the signed informed consent and then will receive the treatment of re-RT combined with FUS (FUS + re-RT) on an…
- Conditions
- Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV), Brain Tumor Recurrent, Brain Tumor Adult
- Trial name
- NCT04988750
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 7 people
- Sponsor
- NaviFUS Corporation
c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
The study assessed the safety and the dose of the combination of INC280 and buparlisib (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent glioblastoma with PTEN mutations, homozygous…
- Trial name
- NCT01870726
- Testing
- INC280, Buparlisib
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme, Astrocytoma, Grade IV
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
The goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus [CMV]-specific T cells and pembrolizumab) in patients with brain cancer.
- Trial name
- TCaP (NCT06157541)
- Testing
- Allogeneic cytomegalovirus-specific T cells, Pembrolizumab
- Where
- 4 sites in Australia
- Volunteers
- 58 people
- Sponsor
- Queensland Institute of Medical Research
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
- Trial name
- 5G-RUBY (NCT06630260)
- Testing
- Avutometinib, Defactinib, Temozolomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 182 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Astrocytoma, Grade IV, Glioblastoma
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
The main purposes of this study are: I. To assess that the four habitats within the tumor (HAT and LAT) and edema (IPE and VPE) in high-grade glioma are different at vascular, tissular, cellular and molecular levels. II.
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype
- Trial name
- BIOhabitats (NCT05375318)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Juan M Garcia-Gomez
Glioblastoma, Malignant Glioma
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioma, Refractory Glioma
- Trial name
- NCT03389230
- Testing
- HER2(EQ)BBζ/CD19t+ T cells, Laboratory Biomarker Analysis, Leukapheresis
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT01172964
- Testing
- flucytosine, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Compliance, Patient, Glioblastoma
Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields
The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention in a multi-center, randomized controlled trial.
- Conditions
- Compliance, Patient, Glioblastoma, Astrocytoma, Grade IV
- Trial name
- COCOON (NCT06017063)
- Testing
- Psychological intervention
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing…
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV
- Trial name
- NCT05789394
- Testing
- Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Glioblastom WHO Grade 4
Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
Locoregional, intracavitary radioimmunotherapy (iRIT) with a newly developed radioimmunoconjugate (Lu-177 labeled 6A10-Fab-fragments) will be used to prevent or postpone tumour recurrence in patients with GBM following standard…
- Trial name
- RIT in GBM (NCT05533242)
- Testing
- Lu-177 labeled 6A10-Fab-fragments
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Muenster
Adult Glioblastoma, High Grade Glioma
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or…
- Conditions
- Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
- Trial name
- PNOC020 (NCT04573140)
- Testing
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Florida